China Pharma Announces the Entry of "At-The-Market" Equity Offering

Core Viewpoint - China Pharma Holdings, Inc. has filed a prospectus supplement with the SEC to offer and sell shares of common stock with an aggregate offering price of up to $600,000 [1][2] Group 1: Financing Details - The shares will be offered under a Securities Purchase Agreement (SPA) with an investor, allowing the purchase of up to $600,000 worth of common stock from December 12, 2024, to December 31, 2024 [2] - The purchase price will be based on the lower of the closing price the day before the purchase notice or the five-day average closing prices, with a minimum price of $0.15 per share [2] Group 2: Company Overview - China Pharma is a specialty pharmaceutical company focused on developing, manufacturing, and marketing products for high-incidence and high-mortality conditions in China, including cardiovascular, CNS, infectious, and digestive diseases [5] - The company operates a cost-effective business model driven by market demand and has a nationwide distribution network across major cities and provinces in China [5]